Nasdaq

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the results from ...
Stockhouse

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5 ...
Business Wire

Checkpoint Systems Expands Health and Beauty RFID Label Portfolio For Improved Merchandise Visibility

THOROFARE, N.J.--(BUSINESS WIRE)--Checkpoint Systems, Inc. (NYSE:CKP), a leading global supplier of merchandise availability solutions for the retail industry, today announced that it has expanded its ...
FoodNavigator

Roadmap navigates FDA label changes

Food Label Compass, a joint project by FoodMinds, Nutrition Impact and EAS Consulting Group, helps food firms navigate sweeping changes to US labeling requirements. The US Food and Drug Administration ...